Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Melanoma: Clinical Trials and Translational Research
share announcement

Melanoma: Clinical Trials and Translational Research

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 339

Special Issue Editors

Dr. Roberta Giuffrida

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy
Interests: dermato-oncology; melanoma; non-melanoma skin cancer; signaling pathways; targeted therapy; artificial intelligence; noninvasive skin imaging; autoimmune/autoinflammatory skin diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Claudio Guarneri

E-Mail Website
Guest Editor
Department of Biomedical and Dental Sciences and Morpho Functional Imaging, University of Messina, Messina, Italy
Interests: Melanoma; Clinical Dermatology; Psoriasis; Treatment; Skin; Cosmetic Surgery; Pathogens; Infection; Diagnosis; Biomarkers; Targeted Therapy; Autoimmune/Autoinflammatory Skin Disease
Special Issues, Collections and Topics in MDPI journals
Dr. Linda Tognetti

E-Mail Website
Guest Editor
Dermatology Unit, Department of Medical, Surgical and Neurosciences, University of Siena, Siena, Italy
Interests: dermato-oncology; melanoma; non-melanoma skin cancer; noninvasive skin imaging; artificial intelligence; pediatric dermatology; translational dermo-research; photobiology
Dr. Claudio Conforti

E-Mail Website
Guest Editor
Dermatology Clinic of Trieste, Maggiore Hospital, University of Trieste, Trieste, Italy
Interests: dermato-oncology; general dermatology; melanoma; non-melanoma skin cancer; targeted therapy; immunotherapy; noninvasive skin imaging; aesthetic medicine; dermatologic surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Melanoma is the deadliest type of skin cancer. It arises from melanocytes in skin, mucous membranes, eyes, or the central nervous system, following genetic, epigenetic and allogenetic alterations, and has the potential to spread to any organ of the body. Generally, this tumor can be cured, if diagnosed in the early stages, with high survival rates. However, patients with advanced disease have a poor prognosis.

In the past two decades, much progress has been made in the diagnosis and treatment of melanoma, also thanks to the increased knowledge of tumor biology, which has led to a targeted approach and personalized melanoma therapeutic strategies.

The aim of this Special Issue is to publish innovative and high quality original/review articles focused on the development and improvement of new ways to prevent, diagnose, and treat melanoma by translating findings observed in a laboratory into clinical applications.

We look forward to receiving your contributions.

Dr. Roberta Giuffrida
Dr. Claudio Guarneri
Dr. Linda Tognetti
Dr. Claudio Conforti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • skin cancer
  • biomarkers
  • genomics
  • diagnosis
  • therapy
  • immunotherapy
  • targeted therapy
  • resistance

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 1061 KiB  
Article
Association of miR-146a-5p and miR-21-5p with Prognostic Features in Melanomas
by Maria Naddeo, Elisabetta Broseghini, Federico Venturi, Sabina Vaccari, Barbara Corti, Martina Lambertini, Costantino Ricci, Beatrice Fontana, Giorgio Durante, Milena Pariali, Biagio Scotti, Giulia Milani, Elena Campione, Manuela Ferracin and Emy Dika
Cancers 2024, 16(9), 1688; https://doi.org/10.3390/cancers16091688 - 26 Apr 2024
Viewed by 180
Abstract
Background: Cutaneous melanoma (CM) is one of the most lethal tumors among skin cancers and its incidence is rising worldwide. Recent data support the role of microRNAs (miRNAs) in melanoma carcinogenesis and their potential use as disease biomarkers. Methods: We quantified the expression [...] Read more.
Background: Cutaneous melanoma (CM) is one of the most lethal tumors among skin cancers and its incidence is rising worldwide. Recent data support the role of microRNAs (miRNAs) in melanoma carcinogenesis and their potential use as disease biomarkers. Methods: We quantified the expression of miR-146a-5p and miR-21-5p in 170 formalin-fixed paraffin embedded (FFPE) samples of CM, namely 116 superficial spreading melanoma (SSM), 26 nodular melanoma (NM), and 28 lentigo maligna melanoma (LMM). We correlated miRNA expression with specific histopathologic features including Breslow thickness (BT), histological subtype, ulceration and regression status, and mitotic index. Results: miR-146a-5p and miR-21-5p were significantly higher in NM compared to SSM and LMM. The positive correlation between miR-146a-5p and miR-21-5p expression and BT was confirmed for both miRNAs in SSM. Considering the ulceration status, we assessed that individual miR-21-5p expression was significantly higher in ulcerated CMs. The increased combined expression of the two miRNAs was strongly associated with ulceration (p = 0.0093) and higher mitotic rate (≥1/mm2) (p = 0.0005). We demonstrated that the combination of two-miRNA expression and prognostic features (BT and ulceration) can better differentiate cutaneous melanoma prognostic groups, considering overall survival and time-to-relapse clinical outcomes. Specifically, miRNA expression can further stratify prognostic groups among patients with BT ≥ 0.8 mm but without ulceration. Our findings provide further insights into the characterization of CM with specific prognostic features. The graphical abstract was created with BioRender.com. Full article
(This article belongs to the Special Issue Melanoma: Clinical Trials and Translational Research)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop